Aminopterin in Treating Patients With Refractory Leukemia
Completed · Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory leukemia.
Key facts
- Study ID
- NCT00003305
- Run by
- Genzyme, a Sanofi Company
- People needed
- 75
- Starts
- 1997-07-01
- Expected to finish
- 2007-09-01
- Last updated by the study team
- 2014-01-06
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Advanced Urology Medical Center — Anaheim, California, United States
- South Coast Urological Medical Group — Laguana Hills, California, United States
- Urology Specialists, P.C. — Waterbury, Connecticut, United States
- Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center — Sarasota, Florida, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- 206 Research Associates — Greenbelt, Maryland, United States
- Mid Atlantic Clinical Research — Rockville, Maryland, United States
- Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Medical & Clinical Research Associates, LLC — Bay Shore, New York, United States
- Herbert Irving Comprehensive Cancer Center — New York, New York, United States
- Medical City Dallas Hospital — Dallas, Texas, United States
- Urology Centers of North Texas — Dallas, Texas, United States
- Urology San Antonio Research — San Antonio, Texas, United States
- Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.